The study will also use the HDWear monitor for a clinical study on patient response to anti-chorea medication or subtle motor abnormalities in the premanifest stage of Huntington’s disease.
It is interesting that the press release uses ‘telecare’ for HDWear, which is not much used in the US for behavioral monitoring though perfectly correct. HDWear’s use here builds on the company’s earlier sensors-based systems for telehealth, physical activity monitoring, fall risk assessment and detection. This Editor notes that BioSensics is one of the older telehealth companies still operating (2007), and now is primarily using its devices in research studies. Drug Discovery & Development, Release. Hat tip to Guy Dewsbury via LinkedIn (again)